HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis
NCT ID: NCT01847248
Last Updated: 2013-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
118 participants
OBSERVATIONAL
2011-05-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* HSPA12B is primarily located in endothelial cells and detectable during sepsis.
* The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sepsis
Patients with sepsis but not severe sepsis
No interventions assigned to this group
Severe sepsis
Patients with severe sepsis
No interventions assigned to this group
SIRS
Patients with SIRS after major orthopedics surgery
No interventions assigned to this group
Control
Healthy volunteers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients meet the diagnostic criteria according to the grouping
Exclusion Criteria
* patients who were undergoing continuous renal replacement therapy before sampling
* patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jia-feng Wang
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ke-ming Zhu, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSPA12B-sepsis-biomarker
Identifier Type: -
Identifier Source: org_study_id